<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" dtd-version="1.3"><?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.6.0//EN//XML?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName art560.dtd?><?SourceDTD.Version 5.6.0?><?ConverterInfo.XSLTName elsevier2nlmx2.xsl?><?ConverterInfo.Version 1?><?origin publisher?><?FILEmeta_SYNBIO386 xml ?><?FILEmain xml ?><?FILEmain pdf ?><?FILEgr1 jpg ?><?FILEgr2 jpg ?><?FILEgr3 jpg ?><?FILEgr4 jpg ?><?FILEgr5 jpg ?><?FILEmmc1 docx ?><?FILEmmc2 xlsx ?><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Synth Syst Biotechnol</journal-id><journal-id journal-id-type="iso-abbrev">Synth Syst Biotechnol</journal-id><journal-title-group><journal-title>Synthetic and Systems Biotechnology</journal-title></journal-title-group><issn pub-type="epub">2405-805X</issn><publisher><publisher-name>KeAi Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">10413001</article-id><article-id pub-id-type="pii">S2405-805X(23)00057-1</article-id><article-id pub-id-type="doi">10.1016/j.synbio.2023.07.003</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Targeted genome mining for microbial antitumor agents acting through DNA intercalation</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Zhao</surname><given-names>Zhijie</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Zhao</surname><given-names>Guiyun</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Chai</surname><given-names>Yi</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Li</surname><given-names>Wei</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Song</surname><given-names>Kaihui</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Zhao</surname><given-names>Wenbin</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Li</surname><given-names>Hairong</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au8"><name><surname>Wu</surname><given-names>Miaolian</given-names></name><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au9"><name><surname>Zhou</surname><given-names>Zhan</given-names></name><email>zhanzhou@zju.edu.cn</email><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff4" ref-type="aff">d</xref><xref rid="cor2" ref-type="corresp">&#x02217;&#x02217;</xref></contrib><contrib contrib-type="author" id="au10"><name><surname>Du</surname><given-names>Yi-Ling</given-names></name><email>yldu@zju.edu.cn</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff4" ref-type="aff">d</xref><xref rid="aff5" ref-type="aff">e</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><aff id="aff1"><label>a</label>The Fourth Affiliated Hospital and Department of Microbiology, School of Medicine, Zhejiang University, Hangzhou, 310058, China</aff><aff id="aff2"><label>b</label>Yong Loo Lin School of Medicine, National University of Singapore, Singapore</aff><aff id="aff3"><label>c</label>Innovation Institute for Artificial Intelligence in Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China</aff><aff id="aff4"><label>d</label>The Fourth Affiliated Hospital, School of Medicine, Zhejiang University, Yiwu, 322000, China</aff><aff id="aff5"><label>e</label>Zhejiang Provincial Key Laboratory for Microbial Biochemistry and Metabolic Engineering, Hangzhou, 310058, China</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author. The Fourth Affiliated Hospital and Department of Microbiology, School of Medicine, Zhejiang University, Hangzhou, 310058, China. <email>yldu@zju.edu.cn</email></corresp><corresp id="cor2"><label>&#x02217;&#x02217;</label>Corresponding author. Innovation Institute for Artificial Intelligence in Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China. <email>zhanzhou@zju.edu.cn</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>22</day><month>7</month><year>2023</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>9</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>22</day><month>7</month><year>2023</year></pub-date><volume>8</volume><issue>3</issue><fpage>520</fpage><lpage>526</lpage><history><date date-type="received"><day>24</day><month>6</month><year>2023</year></date><date date-type="rev-recd"><day>18</day><month>7</month><year>2023</year></date><date date-type="accepted"><day>18</day><month>7</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; 2023 The Authors</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="abs0010"><p>Microbial natural products have been one of the most important sources for drug development. In the current postgenomic era, sequence-driven approaches for natural product discovery are becoming increasingly popular. Here, we develop an effective genome mining strategy for the targeted discovery of microbial metabolites with antitumor activities. Our method employs <italic>uvrA</italic>-like genes as genetic markers, which have been identified in the biosynthetic gene clusters (BGCs) of several chemotherapeutic drugs of microbial origin and confer self-resistance to the corresponding producers. Through systematic genomic analysis of gifted actinobacteria genera, identification of <italic>uvrA</italic>-like gene-containing BGCs, and targeted isolation of products from a BGC prioritized for metabolic analysis, we identified a new tetracycline-type DNA intercalator timmycins. Our results thus provide a new genome mining strategy for the efficient discovery of antitumor agents acting through DNA intercalation.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Genome mining</kwd><kwd>Microbial natural product</kwd><kwd>DNA intercalator</kwd><kwd>UvrA-like protein</kwd><kwd>Biosynthetic gene clusters</kwd><kwd>Tetracycline</kwd></kwd-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0010">Microbial specialized metabolites are rich sources of antibiotics and clinically used drugs [<xref rid="bib1" ref-type="bibr">[1]</xref>, <xref rid="bib2" ref-type="bibr">[2]</xref>, <xref rid="bib3" ref-type="bibr">[3]</xref>]. These small molecules disrupt essential cellular processes through various modes of action. Historically, compounds of interest were isolated through large-scale screening of microbial culture extracts followed by activity tracking based on specific bioactivity assays. However, this traditional bioactivity-guided strategy is becoming less efficient due to the high rate of rediscovery of known compounds. In recent years, great efforts have been made to elucidate the biosynthetic pathways of microbial specialized metabolites with diversified structures and activities [<xref rid="bib4" ref-type="bibr">4</xref>,<xref rid="bib5" ref-type="bibr">5</xref>]. These studies not only revealed novel enzymology involved in the microbial specialized metabolism but also significantly increased our understanding of the self-resistance mechanisms of the producers, as it was found that self-resistance genes are frequently clustered with biosynthetic genes [<xref rid="bib6" ref-type="bibr">6</xref>]. This co-localization property facilitates the identification of biosynthetic genes of a given microbial metabolite and offers genome mining approaches for the discovery of new compounds with predictable modes of action in the postgenomic era. Indeed, several self-resistance-guided strategies for identifying new bioactive compounds have been reported [<xref rid="bib7" ref-type="bibr">[7]</xref>, <xref rid="bib8" ref-type="bibr">[8]</xref>, <xref rid="bib9" ref-type="bibr">[9]</xref>, <xref rid="bib10" ref-type="bibr">[10]</xref>, <xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib12" ref-type="bibr">[12]</xref>].</p><p id="p0015">One family of bacteria-derived antitumor and antimicrobial agents is DNA intercalators, which can insert into the DNA double helix through noncovalent interactions, leading to DNA structural changes and replication arrest [<xref rid="bib13" ref-type="bibr">13</xref>,<xref rid="bib14" ref-type="bibr">14</xref>]. Molecules from this class include chemotherapeutic anthracycline doxorubicin, enediyne C-1027, depsipeptide thiocoraline, and aurealic acid mithramycin [<xref rid="bib14" ref-type="bibr">14</xref>]. These molecules are biosynthetically assembled by different enzymatic machinery and are structurally distinct from each other. It was found that the biosynthetic gene clusters (BGCs) of these compounds encode UvrA-like proteins that can confer self-protection to the producers. Examples include DrrC from the daunorubicin BGC [<xref rid="bib15" ref-type="bibr">15</xref>], Ecm16 from the echinomycin BGC [<xref rid="bib16" ref-type="bibr">16</xref>], and MtrX from the mithramycin BGC [<xref rid="bib17" ref-type="bibr">17</xref>] (<xref rid="fig1" ref-type="fig">Fig. 1</xref>). Canonical UvrA is part of the UvrABCD nucleotide excision repair (NER) system [<xref rid="bib18" ref-type="bibr">18</xref>]. UvrA participates in the initial ATP-dependent DNA scanning and damage recognition through direct UvrA-DNA interactions. This is followed by the recruitment of UvrB and UvrC for nucleotide excision. Although the detailed self-resistance mechanism of the UvrA-like protein family is still not fully understood, preliminary studies of DrrC and Ecm16 suggested that they also depend on ATP for their normal functions [<xref rid="bib19" ref-type="bibr">19</xref>]. However, unlike canonical UvrA, they lack a UvrB-binding domain and can render self-protection independent of the host UvrABC system.<fig id="fig1"><label>Fig. 1</label><caption><p>Selected antitumor microbial natural products that target DNA through noncovalent interactions. (a) Examples of antitumor microbial natural products. (b) The biosynthetic gene clusters (BGCs) of compounds in (a). The <italic>uvrA</italic>-like genes are highlighted in red.</p></caption><alt-text id="alttext0020">Fig. 1</alt-text><graphic xlink:href="gr1"/></fig></p><p id="p0020">In this study, we explored the potential of utilizing the <italic>uvrA</italic>-like gene as a genetic marker for the targeted isolation of new anticancer and antimicrobial agents through genome mining. Through systematic genome analysis of gifted Actinobacteria genera, prediction and classification of UvrA-like gene-containing BGCs, and metabolic analysis of a strain prioritized for target compound isolation, we identified new tetracycline-type DNA intercalator timmycins. Together, our results reported a new genome mining strategy for the efficient isolation of antibacterial and antitumor agents acting through DNA intercalation.</p></sec><sec id="sec2"><label>2</label><title>Material and methods</title><sec id="sec2.1"><label>2.1</label><title>General methods</title><p id="p0025">DNA primers were purchased from Tsingke Biological Technology. Reagents were purchased from Sigma&#x02012;Aldrich, New England Bio Labs, and Bio Basic Inc. DNA manipulations of <italic>Escherichia coli</italic> and <italic>Actinomadura</italic> were carried out according to standard procedures. Strain <italic>Actinomadura</italic> sp. ATCC 31491 was maintained on MSF agar (2% (w/v) mannitol, 2% soy flour, 2% agar). Apramycin (50&#x000a0;&#x003bc;g&#x000a0;mL<sup>&#x02212;1</sup>), kanamycin (50&#x000a0;&#x003bc;g&#x000a0;mL<sup>&#x02212;1</sup>), and nalidixic acid (25&#x000a0;&#x003bc;g&#x000a0;mL<sup>&#x02212;1</sup>) were used for the selection of recombinant strains.</p></sec><sec id="sec2.2"><label>2.2</label><title>Gene inactivation in <italic>Actinomadura</italic> strain</title><p id="p0030">For the construction of a gene knock-out mutant in <italic>Actinomadura</italic> sp. ATCC 31491, two &#x0223c;3&#x000a0;kb homologous arms flanking the targeted region were amplified by PCR using genomic DNA of <italic>Actinomadura</italic> sp. ATCC 31491 as templates. These segments were assembled into linearized pYD69 through seamless cloning [<xref rid="bib20" ref-type="bibr">20</xref>]. After confirmation by DNA sequencing, the obtained vector was introduced into methylation-deficient <italic>E. coli</italic> ET12567/pUZ8002 for <italic>E. coli</italic>-<italic>Actinomadura</italic> conjugation. Exconjugants were obtained after selection for apramycin resistance. After several rounds of nonselective growth, replica plating and PCR were then used to screen the apramycin-sensitive colonies for gene knockout mutants (<xref rid="appsec1" ref-type="sec">Fig. S1</xref>).</p></sec><sec id="sec2.3"><label>2.3</label><title>Metabolic analysis of <italic>Actinomadura</italic> strains</title><p id="p0035">For the metabolic analysis, strain <italic>Actinomadura</italic> sp. ATCC 31491 and its mutant strain were grown on MSF plates at 30&#x000a0;&#x000b0;C for 10 days until sporulation. These MSF agar plates were then sliced into small pieces, extracted by ethyl acetate, and subjected to HPLC analysis. Analytic HPLC analysis was carried out with an Agilent 1260 HPLC apparatus using an Elipse EC-C18 column (5&#x000a0;&#x003bc;m, 4.6&#x000a0;mm ID&#x000a0;&#x000d7;&#x000a0;150&#x000a0;mm) (detection wavelength: 280&#x000a0;nm). Elution was performed at 1.0&#x000a0;mL/min with a mobile-phase mixture consisting of a linear gradient of water and acetonitrile (both contain 0.05% (v/v) formic acid) as follows: 30%&#x02013;90% acetonitrile in 18&#x000a0;min, 90%&#x02013;100% acetonitrile in 2&#x000a0;min, and then maintained at 100% acetonitrile for 3&#x000a0;min.</p></sec><sec id="sec2.4"><label>2.4</label><title>Compound isolation and structural elucidation</title><p id="p0040">For isolation of compounds, the ethyl acetate extract of <italic>Actinomadura</italic> sp. ATCC 31491 grown on MSF agar was fractionated on a Sephadex LH-20 column with MeOH elution. After analysis with HPLC, the fractions containing metabolites of interest were combined, and the target compounds were purified from these fractions by reversed-phase semipreparative HPLC (YMC-Triart C18, 5&#x000a0;&#x003bc;m, 10&#x000a0;mm ID&#x000a0;&#x000d7;&#x000a0;250&#x000a0;mm) (UV detection at 280&#x000a0;nm). Compounds <bold>1</bold> (40&#x000a0;mg, t<sub>R</sub>&#x000a0;=&#x000a0;33.0&#x000a0;min) and <bold>2</bold> (30.1&#x000a0;mg, t<sub>R</sub>&#x000a0;=&#x000a0;45.0&#x000a0;min) were purified with 52% (acetonitrile+ 0.05% FA)/(H<sub>2</sub>O&#x000a0;+&#x000a0;0.05% FA) at 4&#x000a0;mL/min. The <sup>1</sup>H- and <sup>13</sup>C and 2D NMR spectra were recorded on a Bruker AV-600 MHz spectrometer using CDCl<sub>3</sub> as the solvent.</p></sec><sec id="sec2.5"><label>2.5</label><title>Antibacterial and antitumor activity assays</title><p id="p0045"><italic>S. aureus</italic> subsp. <italic>aureus</italic> Rosenbach ATCC 29213, <italic>E. faecalis</italic> ATCC 19433, and <italic>P</italic>. <italic>aeruginosa</italic> ATCC 27853 were used for antibiotic assays. Briefly, microbial seed cultures were initiated by inoculating 5&#x000a0;mL LB and by growing these overnight at 37&#x000a0;&#x000b0;C and 220&#x000a0;rpm. Each culture was then diluted to an initial OD<sub>600</sub> of 0.02 in a 100&#x000a0;&#x003bc;L volume per well in a 96-well plate, which gave an inoculum of approximately 5&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> to 5&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup>. The wells contained varying concentrations of the compounds tested: 0, 0.096&#x000a0;nM, 19.3&#x000a0;nM, 96&#x000a0;nM, 193&#x000a0;nM, 386&#x000a0;nM, 0.96&#x000a0;&#x003bc;M, 1.93&#x000a0;&#x003bc;M, 3.86&#x000a0;&#x003bc;M, 9.6&#x000a0;&#x003bc;M, 19.3&#x000a0;&#x003bc;M, and 38.6&#x000a0;&#x003bc;M final concentration. Assays were set up in triplicate. Plates were incubated at 37&#x000a0;&#x000b0;C for 16&#x000a0;h. The compounds used for antibiotic assays included mithramycin, timmycin A, and timmycin B.</p><p id="p0050">For cytotoxicity assays, compounds were tested against cell lines (A375, HCT116, HeLa). Cells were seeded as aliquots into 96-well plates at a density of 5&#x000a0;&#x000d7;&#x000a0;10<sup>3</sup>&#x000a0;cells per well in DMEM (Dulbecco's Modified Eagle Medium) supplemented with 10% FBS, 50 IU/mL penicillin and 50&#x000a0;&#x003bc;g&#x000a0;mL<sup>&#x02212;1</sup> streptomycin. After 24&#x000a0;h of incubation at 37&#x000a0;&#x000b0;C, compounds diluted in the same culture medium were added to the cells at final concentrations of 0.08&#x000a0;nM, 8&#x000a0;nM, 80&#x000a0;nM, 0.4&#x000a0;&#x003bc;M, 0.8&#x000a0;&#x003bc;M, 2&#x000a0;&#x003bc;M, 10&#x000a0;&#x003bc;M, and 50&#x000a0;&#x003bc;M. After an additional 48&#x000a0;h of incubation, the cells were first washed twice with PBS buffer, 120&#x000a0;&#x003bc;L of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (0.83&#x000a0;mg/mL) solution was added to each well [<xref rid="bib21" ref-type="bibr">21</xref>], and plates were returned to the incubator for 4&#x000a0;h. After removal of the solution from each well, 150&#x000a0;&#x003bc;L of DMSO was added to lyse the cells and solubilize the purple crystals. The samples were read on a microplate detector at 490&#x000a0;nm. The obtained results were processed using GraphPad Prism 7 software.</p></sec></sec><sec id="sec3"><label>3</label><title>Results and discussion</title><sec id="sec3.1"><label>3.1</label><title>Genome mining of BGCs with <italic>uvrA</italic>-like genes</title><p id="p0055">To explore the distribution of UvrA-like proteins in actinobacteria that are known as gifted natural product producers, we first collected sequences of six UvrA-like proteins from BGCs of known antitumor compounds. These include DrrC (NCBI accession number: <ext-link ext-link-type="uri" xlink:href="ncbi-p:AAB39274" id="intref0010">AAB39274</ext-link>), QncO (AGD95041), MtrX (CAK50795), SgcB2 (ANY94424), Ecm16 (BAE98165), and Luz28 (UKU0991). We then used these sequences as queries for the tblastn searches against the NCBI database (July 2022) of RefSeq genomes of selected <italic>Actinobacteria</italic> genera (<italic>Actinomycetales</italic>, <italic>Frankiales</italic>, <italic>Micromonosporales</italic>, <italic>Streptomycetales</italic>, and <italic>Streptosporangiales</italic>) in the GenBank database [<xref rid="bib22" ref-type="bibr">22</xref>]. Homologous proteins with sequence identity &#x02265;30% and alignment length &#x0003e;600&#x000a0;amino acids were collected. After dereplication, 3820 actinobacteria genomes containing approximately six thousand UvrA/UvrA-like proteins were recovered. Next, the sequences of 40&#x000a0;kb upstream and downstream regions of each <italic>uvrA</italic>/<italic>uvrA</italic>-like gene were collected and then subjected to antiSMASH 6.0 analysis to detect the potential presence of putative BGCs [<xref rid="bib23" ref-type="bibr">23</xref>]. These efforts resulted in 642 BGCs in total.</p><p id="p0060">We then used the BiG-SCAPE tool to construct the sequence similarity networks of these BGCs and group them into eight classes, including PKSs, other PKSs, NRPSs, PKS-NRPS hybrids, RiPPs, saccharides, terpenes, and others [<xref rid="bib24" ref-type="bibr">24</xref>] (<xref rid="fig2" ref-type="fig">Fig. 2</xref>). Our present study focused on the saccharide class for further study. All BGCs from this class contain type II PKS and glycosyltransferase genes, which potentially encode aromatic polyketides decorated with saccharide residues. BGCs of characterized compounds fall into this category, including those for mithramycin, chromomycin A3, cytorhodin Y, and cosmomycin C [<xref rid="bib25" ref-type="bibr">[25]</xref>, <xref rid="bib26" ref-type="bibr">[26]</xref>, <xref rid="bib27" ref-type="bibr">[27]</xref>, <xref rid="bib28" ref-type="bibr">[28]</xref>]. Among them, mithramycin has been approved for clinical anticancer use [<xref rid="bib25" ref-type="bibr">25</xref>]. Carbohydrate moieties have been shown to be essential for the biological properties of these molecules.<fig id="fig2"><label>Fig. 2</label><caption><p>Sequence similarity network (SSN) of BGC obtained using BiG-SCAPE and visualized with Cytoscape 3.9.1. Each node represents a BGC. MiBIG BGCs are labeled with the corresponding product.</p></caption><alt-text id="alttext0025">Fig. 2</alt-text><graphic xlink:href="gr2"/></fig></p></sec><sec id="sec3.2"><label>3.2</label><title>In silico analysis of the tim BGC that is prioritized for further study</title><p id="p0065">Next, we used CORASON to construct a phylogenetic tree of these UvrA-like protein-containing BGCs from the saccharide class [<xref rid="bib24" ref-type="bibr">24</xref>] (<xref rid="fig3" ref-type="fig">Fig. 3</xref>). One BGC from the strain <italic>Actinomadura</italic> sp. ATCC 31491 caught our attention and was prioritized for metabolite characterization (<xref rid="fig3" ref-type="fig">Fig. 3</xref>). This BGC (named here as <italic>tim</italic> BGC) is phylogenetically related to the BGCs of aureolic acids mithramycin and chromomycin, but it falls into an isolated clade. Comparison of the <italic>tim</italic> BGC to those of mithramycin (<italic>mtm</italic> BGC) and chromomycin (<italic>cmm</italic> BGC) revealed that the <italic>tim</italic> BGC lacks a pair of genes (<italic>mtmOIV/mtmW</italic>, <italic>cmmOIV/cmmW</italic>) that are conserved in the <italic>mtm</italic> and <italic>cmm</italic> BGCs (<xref rid="fig4" ref-type="fig">Fig. 4</xref>a, <xref rid="appsec1" ref-type="sec">Table S4</xref>). These genes encode enzymes responsible for the oxidative cleavage of the fourth ring of a tetracyclic precursor, resulting in a tricyclic structure. In addition, the <italic>tim</italic> BGC encodes a putative amidotransferase (TimD), the homolog of which has been demonstrated to catalyze the transamination of malonate to malonamate in the biosynthesis of oxytetracycline, which introduces an amide unit at one terminus of the polyketide backbone [<xref rid="bib29" ref-type="bibr">29</xref>]. The presence of this gene in <italic>tim</italic> BGC suggested that the corresponding product possesses a tetracycline-type amidated aglycon structure.<fig id="fig3"><label>Fig. 3</label><caption><p>CORASON phylogenetic tree of the saccharide class BGCs. Representative BGCs from MiBIG are marked with triangles, and the corresponding natural products are also displayed. The BGC prioritized for further metabolite characterization is labeled with a red circle.</p></caption><alt-text id="alttext0030">Fig. 3</alt-text><graphic xlink:href="gr3"/></fig><fig id="fig4"><label>Fig. 4</label><caption><p>The biosynthetic gene cluster and structures of timmycin. (a) Comparison of the timmycin BGC with the mithramycin and chromomycin A3 BGCs. (b) Metabolic profiling of <italic>Actinomadura</italic> sp. ATCC 31491 and its &#x00394;<italic>timAB</italic> mutant. (c) Structures of timmycin A and B.</p></caption><alt-text id="alttext0035">Fig. 4</alt-text><graphic xlink:href="gr4"/></fig></p></sec><sec id="sec3.3"><label>3.3</label><title>Identification and structure elucidation of timmycins</title><p id="p0070">To identify the product arising from the <italic>tim</italic> BGC, we first generated a mutant strain of <italic>Actinomadura</italic> sp. ATCC 31491 by deleting the <italic>timA</italic> and <italic>timB</italic> genes, which encode the type II PKS ketoacyl synthase KS<sub>&#x003b1;</sub> and KS<sub>&#x003b2;</sub>, respectively. We then compared the metabolic profiling of strain &#x00394;<italic>timAB</italic> with that of the parental strain ATCC 31491 by HPLC analysis of their culture extracts. After screening different culture media, we identified a set of peaks that were only present in the culture extract of the parental strain but not in that of the strain &#x00394;<italic>timAB</italic> (<xref rid="fig4" ref-type="fig">Fig. 4</xref>b). We speculated that these peaks, which displayed similar UV&#x02012;vis spectra, are structural analogs and could derive from the <italic>tim</italic> BGC.</p><p id="p0075">To further structurally characterize these compounds, we set out to isolate the two major components (<bold>1</bold> and <bold>2</bold>) from the large-scale culture of strain <italic>Actinomadura</italic> sp. ATCC 31491. Compound <bold>1</bold> (named as timmycin A) displayed a mass value of <italic>m</italic>/<italic>z</italic> 1316.4943 from HR-ESI-MS, corresponding to the molecular formula C<sub>61</sub>H<sub>83</sub>NO<sub>29</sub> (calcd for 1316.4943, [M+Na]<sup>+</sup>) (<xref rid="appsec1" ref-type="sec">Fig. S2a</xref>). Compound <bold>2</bold> (named as timmycin B) had a molecular formula of C<sub>62</sub>H<sub>85</sub>NO<sub>29</sub> (observed: 1330.5110, calcd for [M+Na]<sup>+</sup>: 1330.5099) (<xref rid="appsec1" ref-type="sec">Fig. S2b</xref>). Their structures were elucidated using a combination of 1D and 2D NMR analysis (<xref rid="fig4" ref-type="fig">Fig. 4</xref>c and <xref rid="appsec1" ref-type="sec">Fig. S3&#x02013;6</xref>). Timmycins contain a tetracycline-type aglycone substituted with two oligosaccharide side chains, including a disaccharide attached to C-8 and a trisaccharide attached to C-12a of the aglycone (<xref rid="fig4" ref-type="fig">Fig. 4</xref>c). The trisaccharide chain consists of <sc>d</sc>-olivose (sugar C), <sc>d</sc>-olivose (sugar D), and 4-<italic>O</italic>-isobutyryl-3-<italic>O</italic>-acetyl-<sc>d</sc>-olivose (sugar E), while the disaccharide contains 4-<italic>O</italic>-methyl-<sc>d</sc>-fuctose (sugar B) and 4-<italic>O</italic>-acetyl-<sc>d</sc>-oliose (sugar A) for timmycin A or 4-<italic>O</italic>-propionyl-<sc>d</sc>-oliose for timmycin B (<xref rid="appsec1" ref-type="sec">Fig. S7</xref>). Timmycins are new glycosylated aromatic polyketides and are distinct from mithramycin and chromomycin in both aglycone and saccharide patterns.</p></sec><sec id="sec3.4"><label>3.4</label><title>Proposed biosynthetic pathway of timmycins</title><p id="p0080">Based on the established knowledge of the biosynthetic pathways of mithramycin/chromomycin and other aromatic polyketides [<xref rid="bib25" ref-type="bibr">25</xref>,<xref rid="bib26" ref-type="bibr">26</xref>], we proposed a biosynthetic route to timmycins (<xref rid="fig5" ref-type="fig">Fig. 5</xref>). The <italic>tim</italic> BGC encodes enzymes necessary for the construction of an aminated tetracyclic core. These include KS<sub>&#x003b1;</sub> (TimA), KS<sub>&#x003b2;</sub> (TimB), acyl carrier protein (TimC), amidotransferase (TimD), aromatase (TimQ), and cyclases (TimY and TimX). Oxygenases TimOI and TimOII are suggested to introduce hydroxyl groups into the polyketide core. The putative C-methyltransferase TimMII and the two O-methyltransferases TimMI and TimMIII could be responsible for three methylation steps occurring on the timmycin aglycone. For the subsequent glycosylation steps, the four glycosyltransferases (TimGI/GII/GIII/GIV) are expected to catalyze the formation of five glycosidic bonds, which are analogous to those of the mithramycin and chromomycin pathways. More specifically, TimGIV and TimGIII, which are similar to CmmGIV (57% identity) and CmmGIII (53% identity) from the chromomycin pathway (<xref rid="appsec1" ref-type="sec">Table S4</xref>), are assumed to sequentially transfer sugar C (by TimGIV), sugar D (by TimGIII), and sugar E (by TimGIV) to the aglycon, whereas TimGI and TimGII, which are more closely related to CmmGI (53% identity) and CmmGII (52% identity), are suggested to install sugars A and B, respectively. As the last steps in timmycin biosynthesis, the sugar <italic>O</italic>-methyltransferase TimF and the two acyltransferases TimKI and TimKII could further tailor the sugar moieties through methylation and acylations.<fig id="fig5"><label>Fig. 5</label><caption><p>The proposed biosynthetic pathway of timmycins.</p></caption><alt-text id="alttext0040">Fig. 5</alt-text><graphic xlink:href="gr5"/></fig></p></sec><sec id="sec3.5"><label>3.5</label><title>Biological activities of timmycins</title><p id="p0085">We next tested the antibacterial and cytotoxic activity of timmycins (<xref rid="tbl1" ref-type="table">Table 1</xref>, <xref rid="tbl2" ref-type="table">Table 2</xref>). Both <bold>1</bold> and <bold>2</bold> have strong antibacterial activity against Gram-positive bacteria, including <italic>Staphylococcus aureus</italic> subsp. <italic>aureus</italic> ATCC 29213 and <italic>Enterococcus faecalis</italic> ATCC 19433 (<xref rid="tbl1" ref-type="table">Table 1</xref>). No antifungal or anti-Gram-negative bacterial activity was observed at the concentration we tested. Compound <bold>1</bold> displays cytotoxicity against cancer cell lines (A375, HCT116, and HeLa) in the submicromolar range (<xref rid="tbl2" ref-type="table">Table 2</xref>).<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Minimum inhibitory concentration (MIC) values of timmycin A and B (<bold>1</bold> and <bold>2</bold>) against common pathogens.</p></caption><alt-text id="alttext0045">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Assays</th><th colspan="3">MIC/&#x003bc;M<hr/></th></tr><tr><th>Mithramycin</th><th>Timmcycin A (1)</th><th>Timmcycin B (2)</th></tr></thead><tbody><tr><td align="left"><italic>Staphylococcus aureus</italic> subsp. <italic>aureus</italic> ATCC 25923</td><td align="left">3.6</td><td align="left">0.7</td><td align="left">0.6</td></tr><tr><td align="left"><italic>Enterococcus faecalis</italic> ATCC 19433</td><td align="left">4.7</td><td align="left">3.1</td><td align="left">3.4</td></tr><tr><td align="left"><italic>Pseudomonas aeruginosa</italic> ATCC 27853</td><td align="left">&#x0003e;38.6</td><td align="left">&#x0003e;38.6</td><td align="left">&#x0003e;38.6</td></tr><tr><td align="left"><italic>Escherichia coli</italic> ATCC 25922</td><td align="left">&#x02013;</td><td align="left">&#x0003e;38.6</td><td align="left">&#x0003e;38.6</td></tr><tr><td align="left"><italic>Stenotrophomonas maltophilia</italic> ATCC 13637</td><td align="left">&#x02013;</td><td align="left">&#x0003e;38.6</td><td align="left">&#x0003e;38.6</td></tr><tr><td align="left"><italic>Klebsiella pneumoniae</italic> subsp. <italic>pneumoniae</italic> ATCC 13883</td><td align="left">&#x02013;</td><td align="left">&#x0003e;38.6</td><td align="left">&#x0003e;38.6</td></tr><tr><td align="left"><italic>Candida albicans</italic> ATCC 90028</td><td align="left">&#x02013;</td><td align="left">&#x0003e;38.6</td><td align="left">&#x0003e;38.6</td></tr></tbody></table></table-wrap><table-wrap position="float" id="tbl2"><label>Table 2</label><caption><p>Cytotoxic assays against selected cancer cell lines.</p></caption><alt-text id="alttext0050">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Assays</th><th colspan="3">IC<sub>50</sub>/&#x003bc;M<hr/></th></tr><tr><th>A375</th><th>HCT116</th><th>HeLa</th></tr></thead><tbody><tr><td align="left">Mithramycin</td><td align="left">0.018</td><td align="left">0.015</td><td align="left">0.032</td></tr><tr><td align="left">Doxorubicin</td><td align="left">0.015</td><td align="left">0.065</td><td align="left">0.166</td></tr><tr><td align="left">Timmcycin A (<bold>1</bold>)</td><td align="left">0.228</td><td align="left">0.194</td><td align="left">0.195</td></tr></tbody></table></table-wrap></p><p id="p0090">To determine the ability of <bold>1</bold> to interact with DNA, we used a gel mobility retardation assay by incubation of <bold>1</bold> with a 0.7&#x000a0;kb genomic DNA fragment randomly selected from the genome of <italic>Actinomadura</italic> sp. ATCC 31491 (<xref rid="appsec1" ref-type="sec">Fig. S8</xref>). We found that <bold>1</bold> affects the mobility of the DNA fragment, indicating that <bold>1</bold> can bind DNA. Next, we investigated the role of the UvrA-like protein TmrX in self-resistance. We introduced <italic>tmrX</italic> into the heterologous host <italic>Streptomyces albus</italic> J1074. A disk diffusion test was then used to evaluate the sensitivity of the resulting strain <italic>S. albus</italic>&#x000a0;+&#x000a0;<italic>tmrX</italic> to <bold>1</bold> (<xref rid="appsec1" ref-type="sec">Fig. S9</xref>). Compared with the control strain <italic>S. albus,</italic> the resistance of <italic>S. albus</italic>&#x000a0;+&#x000a0;<italic>tmrX</italic> to <bold>1</bold> increased significantly. Together, these results supported that <bold>1</bold> exerts its antibacterial and cytotoxic action by interacting with DNA.</p></sec></sec><sec id="sec4"><label>4</label><title>Conclusion</title><p id="p0095">In this study, we developed a new genome mining strategy for the targeted discovery of bacteria-derived antitumor agents. This method is based on the previous observation that the biosynthetic gene clusters of natural DNA intercalators encode a family of UvrA-like proteins for self-resistance, indicating the potential of the <italic>uvrA</italic>-like gene as a genetic marker to guide the identification of BGCs for new DNA intercalators. As a proof of concept, we successfully isolated a new tetracycline-type DNA intercalator, timmycin, from an <italic>Actinomadura</italic> strain. Although self-resistance gene-guided genome mining approaches have been described previously, this is the first time that the <italic>uvrA</italic>-like gene family is used for the targeted isolation of microbial bioactive metabolites. Considering that hundreds of new <italic>uvrA</italic>-like gene-containing BGCs were identified in this study, our genome mining strategy has great potential for the discovery of novel anticancer drug candidates.</p></sec><sec id="sec5"><title>Declaration of competing interest</title><p id="p0100">The authors declare that they have no conflicts of interest.</p></sec><sec id="sec6"><title>CRediT authorship contribution statement</title><p id="p0105"><bold>Zhijie Zhao:</bold> Data curation, Formal analysis, Investigation, Visualization, Writing &#x02013; original draft. <bold>Guiyun Zhao:</bold> Data curation, Formal analysis, Investigation, Visualization. <bold>Yi Chai:</bold> Investigation, Visualization. <bold>Wei Li:</bold> Investigation. <bold>Kaihui Song:</bold> Investigation. <bold>Wenbin Zhao:</bold> Investigation. <bold>Hairong Li:</bold> Investigation. <bold>Miaolian Wu:</bold> Writing &#x02013; review &#x00026; editing. <bold>Zhan Zhou:</bold> Conceptualization, Methodology, Project administration, Resources, Supervision, Validation, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. <bold>Yi-Ling Du:</bold> Conceptualization, Funding acquisition, Methodology, Project administration, Resources, Supervision, Validation, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Atanasov</surname><given-names>A.G.</given-names></name><name><surname>Zotchev</surname><given-names>S.B.</given-names></name><name><surname>Dirsch</surname><given-names>V.M.</given-names></name><name><surname>Supuran</surname><given-names>C.T.</given-names></name></person-group><article-title>Natural products in drug discovery: advances and opportunities</article-title><source>Nat Rev Drug Discov</source><volume>20</volume><year>2021</year><fpage>200</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">33510482</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>D.J.</given-names></name><name><surname>Cragg</surname><given-names>G.M.</given-names></name></person-group><article-title>Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019</article-title><source>J Nat Prod</source><volume>83</volume><year>2020</year><fpage>770</fpage><lpage>803</lpage><pub-id pub-id-type="pmid">32162523</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>B.</given-names></name></person-group><article-title>A new golden age of natural products drug discovery</article-title><source>Cell</source><volume>163</volume><year>2015</year><fpage>1297</fpage><lpage>1300</lpage><pub-id pub-id-type="pmid">26638061</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Fischbach</surname><given-names>M.A.</given-names></name><name><surname>Walsh</surname><given-names>C.T.</given-names></name></person-group><article-title>Assembly line enzymology for polyketide and nonribosomal Peptide antibiotics: logic, machinery, and mechanisms</article-title><source>Chem Rev</source><volume>106</volume><year>2006</year><fpage>3468</fpage><lpage>3496</lpage><pub-id pub-id-type="pmid">16895337</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>C.T.</given-names></name><name><surname>Fischbach</surname><given-names>M.A.</given-names></name></person-group><article-title>Natural products version 2.0: connecting genes to molecules</article-title><source>J Am Chem Soc</source><volume>132</volume><year>2010</year><fpage>2469</fpage><lpage>2493</lpage><pub-id pub-id-type="pmid">20121095</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Medema</surname><given-names>M.H.</given-names></name><name><surname>Kottmann</surname><given-names>R.</given-names></name><name><surname>Yilmaz</surname><given-names>P.</given-names></name><name><surname>Cummings</surname><given-names>M.</given-names></name><name><surname>Biggins</surname><given-names>J.B.</given-names></name><name><surname>Blin</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Minimum information about a biosynthetic gene cluster</article-title><source>Nat Chem Biol</source><volume>11</volume><year>2015</year><fpage>625</fpage><lpage>631</lpage><pub-id pub-id-type="pmid">26284661</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Thaker</surname><given-names>M.N.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Spanogiannopoulos</surname><given-names>P.</given-names></name><name><surname>Waglechner</surname><given-names>N.</given-names></name><name><surname>King</surname><given-names>A.M.</given-names></name><name><surname>Medina</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Identifying producers of antibacterial compounds by screening for antibiotic resistance</article-title><source>Nat Biotechnol</source><volume>31</volume><year>2013</year><fpage>922</fpage><lpage>927</lpage><pub-id pub-id-type="pmid">24056948</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Mill&#x000e1;n-Agui&#x000f1;aga</surname><given-names>N.</given-names></name><name><surname>Zhang</surname><given-names>J.J.</given-names></name><name><surname>O'Neill</surname><given-names>E.C.</given-names></name><name><surname>Ugalde</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>Identification of thiotetronic acid antibiotic biosynthetic pathways by target-directed genome mining</article-title><source>ACS Chem Biol</source><volume>10</volume><year>2015</year><fpage>2841</fpage><lpage>2849</lpage><pub-id pub-id-type="pmid">26458099</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Zang</surname><given-names>X.</given-names></name><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Bat-Erdene</surname><given-names>U.</given-names></name><name><surname>Nguyen</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Resistance-gene-directed discovery of a natural-product herbicide with a new mode of action</article-title><source>Nature</source><volume>559</volume><year>2018</year><fpage>415</fpage><lpage>418</lpage><pub-id pub-id-type="pmid">29995859</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Panter</surname><given-names>F.</given-names></name><name><surname>Krug</surname><given-names>D.</given-names></name><name><surname>Baumann</surname><given-names>S.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>R.</given-names></name></person-group><article-title>Self-resistance guided genome mining uncovers new topoisomerase inhibitors from <italic>myxobacteria</italic></article-title><source>Chem Sci</source><volume>9</volume><year>2018</year><fpage>4898</fpage><lpage>4908</lpage><pub-id pub-id-type="pmid">29910943</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>N.</given-names></name><name><surname>Tang</surname><given-names>Y.</given-names></name></person-group><article-title>Recent developments in self-resistance gene directed natural product discovery</article-title><source>Nat Prod Rep</source><volume>37</volume><year>2020</year><fpage>879</fpage><pub-id pub-id-type="pmid">31912842</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Mungan</surname><given-names>M.D.</given-names></name><name><surname>Alanjary</surname><given-names>M.</given-names></name><name><surname>Blin</surname><given-names>K.</given-names></name><name><surname>Weber</surname><given-names>T.</given-names></name><name><surname>Medema</surname><given-names>M.H.</given-names></name><name><surname>Ziemert</surname><given-names>N.</given-names></name></person-group><article-title>Arts 2.0: feature updates and expansion of the Antibiotic Resistant Target Seeker for comparative genome mining</article-title><source>Nucleic Acids Res</source><volume>48</volume><year>2020</year><fpage>546</fpage><lpage>552</lpage></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Dawson</surname><given-names>S.</given-names></name><name><surname>Malkinson</surname><given-names>J.P.</given-names></name><name><surname>Paumier</surname><given-names>D.</given-names></name><name><surname>Searcey</surname><given-names>M.</given-names></name></person-group><article-title>Bisintercalator natural products with potential therapeutic applications: isolation, structure determination, synthetic and biological studies</article-title><source>Nat Prod Rep</source><volume>24</volume><year>2007</year><fpage>109</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">17268609</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Tenconi</surname><given-names>E.</given-names></name><name><surname>Rigali</surname><given-names>S.</given-names></name></person-group><article-title>Self-resistance mechanisms to DNA-damaging antitumor antibiotics in actinobacteria</article-title><source>Curr Opin Microbiol</source><volume>45</volume><year>2018</year><fpage>100</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">29642052</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Furuya</surname><given-names>K.</given-names></name><name><surname>Richard Hutchinson</surname><given-names>C.</given-names></name></person-group><article-title>The DrrC protein of <italic>Streptomyces peucetius</italic>, a UvrA-like protein, is a DNA-binding protein whose gene is induced by daunorubicin</article-title><source>FEMS Microbiol Lett</source><volume>168</volume><year>1998</year><fpage>243</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">9835035</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>K.</given-names></name><name><surname>Hotta</surname><given-names>K.</given-names></name><name><surname>Praseuth</surname><given-names>A.P.</given-names></name><name><surname>Koketsu</surname><given-names>K.</given-names></name><name><surname>Migita</surname><given-names>A.</given-names></name><name><surname>Boddy</surname><given-names>C.N.</given-names></name><etal/></person-group><article-title>Total biosynthesis of antitumor nonribosomal peptides in <italic>Escherichia coli</italic></article-title><source>Nat Chem Biol</source><volume>2</volume><year>2006</year><fpage>423</fpage><lpage>428</lpage><pub-id pub-id-type="pmid">16799553</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Garcia-Bernardo</surname><given-names>J.</given-names></name><name><surname>Bra&#x000f1;a</surname><given-names>A.F.</given-names></name><name><surname>M&#x000e9;ndez</surname><given-names>C.</given-names></name><name><surname>Salas</surname><given-names>J.A.</given-names></name></person-group><article-title>Insertional inactivation of <italic>mtrX</italic> and <italic>mtrY</italic> genes from the mithramycin gene cluster affects production and growth of the producer organism <italic>Streptomyces argillaceus</italic></article-title><source>FEMS Microbiol Lett</source><volume>186</volume><year>2000</year><fpage>61</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">10779713</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Truglio</surname><given-names>J.J.</given-names></name><name><surname>Croteau</surname><given-names>D.L.</given-names></name><name><surname>Van Houten</surname><given-names>B.</given-names></name><name><surname>Kisker</surname><given-names>C.</given-names></name></person-group><article-title>Prokaryotic nucleotide excision repair: the UvrABC system</article-title><source>Chem Rev</source><volume>106</volume><year>2006</year><fpage>233</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">16464004</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Erlandson</surname><given-names>A.</given-names></name><name><surname>Gade</surname><given-names>P.</given-names></name><name><surname>Menikpurage</surname><given-names>I.P.</given-names></name><name><surname>Kim</surname><given-names>C.-Y.</given-names></name><name><surname>Mera</surname><given-names>P.E.</given-names></name></person-group><article-title>The UvrA-like protein Ecm16 requires ATPase activity to render resistance against echinomycin</article-title><source>Mol Microbiol</source><volume>117</volume><year>2022</year><fpage>1434</fpage><lpage>1446</lpage><pub-id pub-id-type="pmid">35534931</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Werling</surname><given-names>U.</given-names></name><name><surname>Edelmann</surname><given-names>W.</given-names></name></person-group><article-title>Seamless ligation cloning extract (SLiCE) cloning method</article-title><source>Methods Mol Biol Clifton NJ</source><volume>1116</volume><year>2014</year><fpage>235</fpage><lpage>244</lpage></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>van Meerloo</surname><given-names>J.</given-names></name><name><surname>Kaspers</surname><given-names>G.J.L.</given-names></name><name><surname>Cloos</surname><given-names>J.</given-names></name></person-group><article-title>Cell sensitivity assays: the MTT assay</article-title><source>Methods Mol Biol Clifton NJ</source><volume>731</volume><year>2011</year><fpage>237</fpage><lpage>245</lpage></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>O'Neill</surname><given-names>K.R.</given-names></name><name><surname>Haft</surname><given-names>D.H.</given-names></name><name><surname>DiCuccio</surname><given-names>M.</given-names></name><name><surname>Chetvernin</surname><given-names>V.</given-names></name><name><surname>Badretdin</surname><given-names>A.</given-names></name><etal/></person-group><article-title>RefSeq: expanding the Prokaryotic Genome Annotation Pipeline reach with protein family model curation</article-title><source>Nucleic Acids Res</source><volume>49</volume><year>2021</year><fpage>1020</fpage><lpage>1028</lpage></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Blin</surname><given-names>K.</given-names></name><name><surname>Shaw</surname><given-names>S.</given-names></name><name><surname>Kloosterman</surname><given-names>A.M.</given-names></name><name><surname>Charlop-Powers</surname><given-names>Z.</given-names></name><name><surname>van Wezel</surname><given-names>G.P.</given-names></name><name><surname>Medema</surname><given-names>M.H.</given-names></name><etal/></person-group><article-title>antiSMASH 6.0: improving cluster detection and comparison capabilities</article-title><source>Nucleic Acids Res</source><volume>49</volume><year>2021</year><fpage>29</fpage><lpage>35</lpage></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Navarro-Mu&#x000f1;oz</surname><given-names>J.C.</given-names></name><name><surname>Selem-Mojica</surname><given-names>N.</given-names></name><name><surname>Mullowney</surname><given-names>M.W.</given-names></name><name><surname>Kautsar</surname><given-names>S.A.</given-names></name><name><surname>Tryon</surname><given-names>J.H.</given-names></name><name><surname>Parkinson</surname><given-names>E.I.</given-names></name><etal/></person-group><article-title>A computational framework to explore large-scale biosynthetic diversity</article-title><source>Nat Chem Biol</source><volume>16</volume><year>2020</year><fpage>60</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">31768033</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Kormanec</surname><given-names>J.</given-names></name><name><surname>Novakova</surname><given-names>R.</given-names></name><name><surname>Csolleiova</surname><given-names>D.</given-names></name><name><surname>Feckova</surname><given-names>L.</given-names></name><name><surname>Rezuchova</surname><given-names>B.</given-names></name><name><surname>Sevcikova</surname><given-names>B.</given-names></name><etal/></person-group><article-title>The antitumor antibiotic mithramycin: new advanced approaches in modification and production</article-title><source>Appl Microbiol Biotechnol</source><volume>104</volume><year>2020</year><fpage>7701</fpage><lpage>7721</lpage><pub-id pub-id-type="pmid">32686008</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Men&#x000e9;ndez</surname><given-names>N.</given-names></name><name><surname>Nur-e-Alam</surname><given-names>M.</given-names></name><name><surname>Bra&#x000f1;a</surname><given-names>A.F.</given-names></name><name><surname>Rohr</surname><given-names>J.</given-names></name><name><surname>Salas</surname><given-names>J.A.</given-names></name><name><surname>M&#x000e9;ndez</surname><given-names>C.</given-names></name></person-group><article-title>Biosynthesis of the antitumor chromomycin A3 in <italic>Streptomyces griseus</italic>: analysis of the gene cluster and rational design of novel chromomycin analogs</article-title><source>Chem Biol</source><volume>11</volume><year>2004</year><fpage>21</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">15112992</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Gui</surname><given-names>C.</given-names></name><name><surname>Mo</surname><given-names>X.</given-names></name><name><surname>Gu</surname><given-names>Y.-C.</given-names></name><name><surname>Ju</surname><given-names>J.</given-names></name></person-group><article-title>Elucidating the sugar tailoring steps in the cytorhodin biosynthetic pathway</article-title><source>Org Lett</source><volume>19</volume><year>2017</year><fpage>5617</fpage><lpage>5620</lpage><pub-id pub-id-type="pmid">28971684</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Garrido</surname><given-names>L.M.</given-names></name><name><surname>Lomb&#x000f3;</surname><given-names>F.</given-names></name><name><surname>Baig</surname><given-names>I.</given-names></name><name><surname>Nur-e-Alam</surname><given-names>M.</given-names></name><name><surname>Furlan</surname><given-names>R.L.A.</given-names></name><name><surname>Borda</surname><given-names>C.C.</given-names></name><etal/></person-group><article-title>Insights in the glycosylation steps during biosynthesis of the antitumor anthracycline cosmomycin: characterization of two glycosyltransferase genes</article-title><source>Appl Microbiol Biotechnol</source><volume>73</volume><year>2006</year><fpage>122</fpage><lpage>131</lpage><pub-id pub-id-type="pmid">16810496</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Ames</surname><given-names>B.D.</given-names></name><name><surname>Tsai</surname><given-names>S.-C.</given-names></name><name><surname>Tang</surname><given-names>Y.</given-names></name></person-group><article-title>Engineered biosynthesis of a novel amidated polyketide, using the malonamyl-specific initiation module from the oxytetracycline polyketide synthase</article-title><source>Appl Environ Microbiol</source><volume>72</volume><year>2006</year><fpage>2573</fpage><lpage>2580</lpage><pub-id pub-id-type="pmid">16597959</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0115">The following are the Supplementary data to this article:<supplementary-material content-type="local-data" id="mmc1"><caption><title>Multimedia component 1</title></caption><media xlink:href="mmc1.docx"><alt-text>Multimedia component 1</alt-text></media></supplementary-material><supplementary-material content-type="local-data" id="mmc2"><caption><title>Multimedia component 2</title></caption><media xlink:href="mmc2.xlsx"><alt-text>Multimedia component 2</alt-text></media></supplementary-material></p></sec><ack id="ack0010"><title>Acknowledgments</title><p id="p0110">This work was supported by the <funding-source id="gs2">National Key R&#x00026;D Program of China</funding-source> (2019YFA0905400) and the <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source> (32122005).</p></ack><fn-group><fn id="d35e245"><p id="ntpara0010">Peer review under responsibility of KeAi Communications Co., Ltd.</p></fn><fn id="appsec2" fn-type="supplementary-material"><label>Appendix A</label><p id="p0120">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.synbio.2023.07.003" id="intref0015">https://doi.org/10.1016/j.synbio.2023.07.003</ext-link>.</p></fn></fn-group></back></article>